More expert interviews from ACR/ARP 2019

Sangeeta Sule gives a pediatric rheumatologist’s view on a trial looking at tofacitinib for the treatment  of polyarticular juvenile idiopathic arthritis and the potential implementation of the results in the clinic (2:55).

Merete Hetland discusses the NORD-STAR trial findings comparing remission rates after active conventional versus biologic treatment in patients with early rheumatoid arthritis (3:52).  

Laura Coates talks about the COAST-X trial results, and explores how ixekizumab may fit into the treatment paradigm for nonradiographic axial spondyloarthritis (5:12).

Féline Kroon takes us through the results of the HOPE trial, demonstrating that short-term prednisolone treatment may be an option for patients with hand osteoarthritis experiencing a flare following withdrawal of nonsteroidal anti-inflammatory drugs (4:12).

Christian Roux talks us through the findings of the ADEM trial, which demonstrated similar pain outcomes among patients with hand osteoarthritis treated with methotrexate versus placebo (7:05).

Grace Lo outlines the current treatment options for hand osteoarthritis, and comments on whether the findings from the HOPE and ADEM trials will have an impact on clinical practice (5:32).
 

Rona Smith talks about the findings from the RITAZAREM trial, showing that maintenance therapy with rituximab reduces relapse rates compared with azathioprine among patients with ANCA-associated vasculitis (2:09).

Désirée van der Heijde discusses the results of SELECT-AXIS 1, a phase II/III trial demonstrating that upadacitinib may be a promising treatment option for ankylosing spondylitis (2:27).

Oliver FitzGerald comments on the findings from the DISCOVER-1 and DISCOVER-2 trials, which demonstrated the efficacy of guselkumab for the treatment of psoriatic arthritis (3:36).

Laura Coates summarizes the findings for ixekizumab withdrawal in psoriatic arthritis and explains why they present a different picture to what has been seen for axial spondyloarthritis (4:01).

Irene van der Horst Bruinsma discusses the dual benefits of certolizumab pegol for patients with axial spondyloarthritis and a history of acute anterior uveitis (3:32).

Lead investigator Philip Mease outlines the results of the DISCOVER-2 trial, and discusses how guselkumab may impact the psoriatic arthritis treatment landscape (8:26).